Doctors and patients now face uncertainty as the sudden discontinuation poses risks, including severe anemia. The lack of transparency from Pfizer and regulatory agencies raises concerns about patient ...
A man and woman, both with sickle cell, share what their experience was like finding love, and what prospective partners need ...
Earlier this year, STAT’s Eric Boodman reported the heartbreaking story of how, for decades, doctors have pressured sickle ...
Patients with sickle cell anemia (SCA) and persistent albuminuria (PA) exhibited significantly higher levels of urinary ...
About 100,000 Americans, mostly Black, have sickle cell disease, shortening lifespans, delaying puberty, damaging spleens and ...
Sickle cell trait (SCT) differs vastly from sickle cell disease. SCT is a genetic condition when someone inherits one sickle ...
A Johns Hopkins analysis commissioned by STAT shows that the rate of postpartum sterilization is significantly higher in ...
Current sickle cell disease treatment options include: A cornerstone of SCD treatment since 1988, hydroxyurea works by increasing the production of hemoglobin F, which helps prevent the formation of ...
The RUBY Trial is showing promise in treating patients fighting sickle cell disease, and Ohio is setting a national standard ...
(Bloomberg) -- European regulators suspended the approval of Pfizer Inc.’s sickle cell anemia drug, Oxbryta, citing a higher rate of disease complications in patients who started taking it.
SAFETY PROGRAM. TIME FOR FIVE ON YOUR HEALTH. WE’RE FOCUSING ON SICKLE CELL DISEASE. IT IS A PAINFUL, INHERITED CONDITION THAT PRIMARILY AFFECTS AFRICAN AMERICANS. HERE WITH SOME INSIGHT IS ...
Sept 26 (Reuters) - U.S. drugmaker Pfizer (PFE.N), opens new tab said on Wednesday it was withdrawing its sickle cell disease treatment Oxbryta from all markets where it is approved, citing risks ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback